Oracle Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$12.2M |
| 2 |
Ardelyx
ARDX
|
+$10.1M |
| 3 |
GeneDx Holdings
WGS
|
+$5.69M |
| 4 |
Biohaven
BHVN
|
+$4.38M |
| 5 |
EyePoint Inc
EYPT
|
+$1.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teladoc Health
TDOC
|
+$2.43M |
| 2 |
QuidelOrtho
QDEL
|
+$1.13M |
| 3 |
AGEN
Agenus
AGEN
|
+$232K |
| 4 |
VTNR
Vertex Energy, Inc
VTNR
|
+$170K |
| 5 |
Pacific Biosciences
PACB
|
+$122K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.72% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Energy | 0% |
Similar funds
Oracle Investment Management's Q1 2024 Portfolio in Review
As of Q1 2024, Oracle Investment Management held 32 positions worth $150M, down 8.5% from $164M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Oracle Investment Management withdrew a net $14M in Q1 2024, closing 5 positions and reducing 10 holdings. Its most notable exit was Teladoc Health, an estimated $2.43M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 56% a quarter earlier, followed by Consumer Discretionary and Energy.
Against the trend, Oracle Investment Management opened a new position in CAVA Group worth $1.23M.
- Oracle Investment Management's largest Q1 2024 buy was CAVA Group: 17,600 shares worth $1.23M.
- Oracle Investment Management added most to SpringWorks Therapeutics in Q1 2024, an estimated $12.2M increase.
- Oracle Investment Management's biggest Q1 2024 reduction was QuidelOrtho, cutting an estimated $1.13M.
- Oracle Investment Management fully exited Teladoc Health in Q1 2024, selling an estimated $2.43M.
- Oracle Investment Management's ten largest holdings make up 88% of its $150M portfolio in Q1 2024.
- Oracle Investment Management opened 6 new positions and closed 5 in Q1 2024.
- Oracle Investment Management's portfolio value fell 8.5% quarter-over-quarter to $150M.
Based on Oracle Investment Management's 13F filing for Q1 2024, filed 15 May 2024.